Advertisement

ALL Transretinoic Acid Followed by Intensive Chemotherapy in Newly Diagnosed Acute Promyelocytic Leukemia: A Pilot Study on 27 Cases

  • P. Fenaux
  • S. Castaigne
  • H. Dombret
  • E. Archimbaud
  • M. Duarte
  • T. Lamy
  • A. Guerci
  • H. Tilly
  • P. Maloisel
  • D. Bordessoule
  • A. Sadoun
  • C. Chomienne
  • L. Degos
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

Anthracyc1ine (or its derivatives) and cytosine arabinoside (Ara C) combinations give complete remission (CR), in 70 to 75% of cases of acute promyelocytic leukemia (APL) and 35 to 40% of patients achieving CR are cured with adequate consolidation therapy [1–5]. However, 25 to 30% of the patients failure to achieve CR, because of death due to DIC, or sepsis during the chemotherapy induced period of aplasia rather than because of true leukemic resistance, which is rare in APL. All transretinoic acid (ATRA) has selective in vitro and in vivo differentiating activity on abnormal promyelocytes in APL and is capable of inducing a high CR rate in newly diagnosed and relapsing APL [6–11]. Treatment with ATRA leads to rapid improvement of DIC, without any phase of aplasia, suggesting that ATRA may reduce the 2 main causes of failure to achieve CR with chemotherapy in APL. However, ATRA may be associated to rapidly developing hyperleucocytosis, leading to life threatening leucostasis [15–18] and patients who achieve CR with ATRA and are maintained on ATRA alone usually rapidly relapse. This lead us to start a pilot phase of A TRA followed by intensive chemotherapy in newly diagnosed APL. The purpose of intensive chemotherapy was to reduce leukocyte counts in patients with rapidly developing hyperleukocyfosis and to prolong remission duration in all cases.

Keywords

Complete Remission Acute Promyelocytic Leukemia Intensive Chemotherapy Cytosine Arabinoside Pilot Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bernard J, Weil M, Boiron M et al. (1973) Acute promyelocytic leukemia. Results of treatment with daunorubicin. Blood 41: 489–96PubMedGoogle Scholar
  2. 2.
    Marty M, Ganem G, Fischer J et al. (1984) Leucémie aiguë promyélocytaire: étude retrospective de 119 malades traités par daunorubicine. Nouv Rev Fr Hématol 24: 371–78Google Scholar
  3. 3.
    Cunningham I, Gee T, Reich L et al. (1989) Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73: 1116–22PubMedGoogle Scholar
  4. 4.
    Fenaux P, Pollet JP, Vandenbossche L, Dupriez B, Jouet JP, Bauters F (1991) Treatment of acute pro myelocytic leukemia: a report on 70 cases. Leuk. and Lymphoma 4: 249–56CrossRefGoogle Scholar
  5. 5.
    Fenaux P, Tertian G, Castaigne S et al. (1991) A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol 9: 1556–1561PubMedGoogle Scholar
  6. 6.
    Meng-Er H, Yu-Chen Y, Shu-Rong C et al. (1988) Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–72Google Scholar
  7. 7.
    Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L (1990) All trans retinoic acid as a differentiating therapy for acute pro myelocytic leukemias. I. Clinical results. Blood 76: 1704PubMedGoogle Scholar
  8. 8.
    Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, Castaigne S (1990) Treatment of first relapse in acute promyelocytic leukaemia with all trans retinoic acid. Lancet ii: 1440CrossRefGoogle Scholar
  9. 9.
    Chen ZX, Xue YQ, Zhang R et al.(1991) A clinical and experimental study on all trans retinoic acid treated acute promyelocytic leukemia patients. Blood 78: 1413–1419PubMedGoogle Scholar
  10. 10.
    Warrel RP, Stanley MD, Frankel R, Wilson MD, Miller H et al. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid). N Engl J Med 324: 1385–93CrossRefGoogle Scholar
  11. 11.
    Fenaux P, Degos L (1991) Treatment of acute promyelocytic leukemia with all trans retinoic acid. Leuk Res 8: 655CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • P. Fenaux
    • 1
  • S. Castaigne
    • 1
  • H. Dombret
    • 1
  • E. Archimbaud
    • 1
  • M. Duarte
    • 1
  • T. Lamy
    • 1
  • A. Guerci
    • 1
  • H. Tilly
    • 1
  • P. Maloisel
    • 1
  • D. Bordessoule
    • 1
  • A. Sadoun
    • 1
  • C. Chomienne
    • 1
  • L. Degos
    • 1
  1. 1.Departments of Hematology of LilleService of Blood DiseasesLilleFrance

Personalised recommendations